SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (300)10/27/2005 8:32:00 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 447
 
Contrary to RCC regime, DNA is running PIII NSCLC (second line) where Tarceva is primary agent and Avastin is secondary (controlled by placebo). I guess DNA is confident (based on their knowledge of the PII data) that BR-21 study results can be repeated and that Avastin will add benefit to Tarceva regime.

Q: What if Tarceva arm came short of expectation?
A: DNA washes their hand!

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News